At present, PD-1 (Fan et al., 2021) and CTLA-4 (Sun et al., 2020) inhibitors have been validated to benefit patients with advanced NSCLC in clinical trials. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.